Philippe Lucas

Director, Research and Safe Access at MAPS

Data updated

Papers

9 publications

Trials

0 clinical trials

Links

Website

Research Footprint

Philippe Lucas appears in 9 tracked papers (2013–2026), most studied alongside Ayahuasca, Psilocybin and LSD, across Substance Use Disorders (SUD), Depressive Disorders and Anxiety Disorders.

Most-cited paper: Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada (323 citations).

Frequent co-authors: Kenneth Tupper, Kevin Boehnke and Daniel Kruger.

Background & Research

Philippe Lucas, PhD, is a cannabis and psychedelic researcher and safe-access advocate. He earned graduate degrees from the University of Victoria and has held research and advocacy roles focused on psychedelic medicine, public health, and drug policy. He is currently a Research Affiliate at the University of Michigan’s Psychedelic Center and a Director at MAPS.

Key Impact

He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.

9

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

11 collaborators· click a node to visit their profile

Full network →

Compounds

AyahuascaPsilocybinLSDMDMA

Topics

Substance Use Disorders (SUD)Depressive DisordersAnxiety DisordersPTSDImplementation & Service DeliveryTobacco/Nicotine Use Disorder (TUD)MicrodosingSuicidalityPalliative & End-of-Life DistressMajor Depressive Disorder (MDD)

Top Collaborators

Affiliations

Institutions, companies, and organisations Philippe Lucas is associated with.

MAPS

nonprofit

MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.

View stakeholder →